These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24550678)

  • 1. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
    Sweeting AN; Tabet E; Caterson ID; Markovic TP
    Diabetes Metab Syndr Obes; 2014; 7():35-44. PubMed ID: 24550678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
    Garvey WT
    Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and safety of the new anti-obesity medications.
    Hainer V; Aldhoon-Hainerová I
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
    Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
    J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phentermine and topiramate for the management of obesity: a review.
    Cosentino G; Conrad AO; Uwaifo GI
    Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy for obesity.
    Joo JK; Lee KS
    J Menopausal Med; 2014 Dec; 20(3):90-6. PubMed ID: 25580419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G; Cheng-Lai A
    Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment of obesity in the cardiovascular patient.
    Charakida M; Tousoulis D; Finer N
    Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity.
    Kim A; Nguyen J; Babaei M; Kim A; Geller DH; Vidmar AP
    Adolesc Health Med Ther; 2023; 14():125-140. PubMed ID: 37641650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.